VA Consolidation in Intermediate-Risk AML

NCT07672262 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

226

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Intermediate Risk Acute Myeloid Leukemia
Consolidation Therapy

Interventions

DRUG: Venetoclax and Azacitidine
DRUG: Cytarabine ± Anthracycline

Sponsor

The First Affiliated Hospital of Soochow University